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Cerebral ischemia is the leading cause of morbidity and mortality following aneurysmal sub-
arachnoid hemorrhage (SAH). Although 70% of the patients show angiographic vasospasm
only 30% develop symptomatic vasospasm defined as delayed cerebral ischemia (DCI).
Early detection and management of reversible ischemia is of critical importance in patients
with SAH. Using a bedside Xenon enhanced computerized tomography (Xenon-CT) scan-
ner makes it possible to measure quantitative regional Cerebral blood flow (CBF) bedside in
the neurointensive care setting and intracerebral microdialysis (MD) is a method that offers
the possibility to monitor the metabolic state of the brain continuously. Here, we present
results from nine SAH patients with both MD monitoring and bedside Xenon-CT measure-
ments. CBF measurements were performed within the first 72 h following bleeding. Six
out of nine patients developed DCI at a later stage. Five out of six patients who devel-
oped DCI had initial global CBF below 26 ml/100 g/min whereas one had 53 ml/100 g/min.
The three patients who did not develop clinical vasospasm all had initial global CBF above
27 ml/100 g/min. High lactate/pyruvate (L/P) ratio was associated with lower CBF values in
the area surrounding the catheter. Five out of nine patients had L/P ratio ≥25 and four of
these patients had CBF≤22 ml/100 g/min.These preliminary results suggest that patients
with initially low global CBF on Xenon-CT may be more likely to develop DCI. Initially low
global CBF was accompanied with metabolic disturbances determined by the MD. Most
importantly, pathological findings on the Xenon-CT and MD could be observed before any
clinical signs of DCI. Combining bedside Xenon-CT and MD was found to be useful and
feasible. Further studies are needed to evaluate if DCI can be detected before any other
signs of DCI to prevent progress to infarction.
Keywords: cerebral blood flow, subarachnoid hemorrhage, neurointensive care, Xenon-CT, imaging, vasospasm,
microdialysis
INTRODUCTION
Positron emission tomography (PET) studies have shown that
subarachnoid hemorrhage (SAH) causes both global and focal
hemodynamic and metabolic disturbances in the brain early after
aneurysm rupture (1), which makes the brain vulnerability for
secondary insults (2–4). Secondary ischemic brain injury may be
caused by cerebral vasospasm and also by various other secondary
insults, e.g., high intracranial pressure (ICP), hypotension, hypox-
emia, and seizures. Microcirculatory dysfunction, microthrombo-
sis, cortical spreading depression, inflammation, and disturbances
in cerebral autoregulation are today considered to be important
mechanisms for the development of secondary ischemia in SAH (3,
5). Vasospasm is defined as the narrowing of intracranial arteries.
The clinical definition of vasospasm has often been based on the
methods applied for diagnosis such as angiography, transcranial
Doppler (TCD), symptomatology, and imaging (5). Using clinical
definitions, cerebral vasospasm has shown to be the leading cause
of morbidity and mortality following aneurysmal SAH (6). It is
estimated that 70% of the patients develop vasospasm diagnosed
by angiography (7, 8), while only 30–50% develop symptomatic
vasospasm (9, 10). This discrepancy between angiographic find-
ings and development of clinical signs is one of the reasons why the
role of macrovascular narrowing has been questioned as the major
mechanism for the development of ischemia. Current guidelines
of the critical care management of patients with SAH recommend
the use of the term delayed cerebral ischemia (DCI), defined as
focal neurological impairment or decrease of Glasgow coma score,
and/or radiological signs of ischemia/infarction (11).
Reduced cerebral blood flow (CBF) becomes symptomatic
below the critical threshold for electrical/functional disturbances
(12, 13). If sustained, it will lead to irreversible ischemia and
finally infarction. Thus early detection of low CBF is of critical
importance in patients with SAH.
Currently, the detection of vasospasm is routinely based on
the repeated neurological examinations, TCD blood flow veloc-
ity measurements and angiography. When treating patients with
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severe SAH, it would be desirable to have more accurate meth-
ods for the measurements of regional and global CBF at the
bedside in the neurointensive care (NIC) unit. A few centers
have used a bedside Xenon enhanced computerized tomogra-
phy (Xenon-CT) in the NIC setting, and their experiences indi-
cate that this may be an attractive solution (14–16). Xenon-
CT has been shown to be feasible and valuable in detecting
early signs of vasospasm/low CBF and to predict development
of infarction (17, 18). Hypoperfusion measured by Xenon-CT
during the first 24 h following SAH has been shown to cor-
relate with worse outcome (19). We have introduced a new
protocol for the management of SAH patients at our depart-
ment adding bedside Xenon-CT to current neuromonitoring in
order to measure CBF. Here, we present our first results from
nine patients suffering from severe SAH who were examined
with Xenon-CT and simultaneously monitored by intracerebral
microdialysis (MD).
MATERIALS AND METHODS
STUDY POPULATION AND STUDY DESIGN
Nine patients with aneurysmal SAH who were admitted to
the Department of Neurosurgery, Uppsala University Hospital,
between October 2012 and July 2013 were included in the study
(Table 1). All but one of the nine patients were female. The average
age was 56.2± 13.2.
Inclusion criteria were mechanically ventilated SAH patients
with intraventricular catheter and MD monitoring who under-
went Xenon-CT within 72 h of symptom onset. Patients with a
pre-existing neurological deficit or a SAH resulting from trauma
or arterio-venous malformation (AVM) were excluded. The SAH
was verified by CT scanning and the aneurysm was visualized by
a CT angiography or digital subtraction angiography. All patients
included in the study were enrolled within 24 h from the onset of
SAH. All patients underwent surgical clipping (n= 1) or endovas-
cular coiling (n= 8) of the ruptured aneurysm within the first
day except one patient who underwent endovascular coiling after
2 days.
NEUROINTENSIVE CARE
All SAH patients were managed according to a standardized pro-
tocol based on intensive physiological monitoring and aggressive
therapy of any derangement to avoid or minimize secondary brain
injury (4). All unconscious patients and patients with clinical and
radiological signs of intracranial hypertension received a ven-
triculostomy. If ICP was above 20 mmHg, the drainage system
was opened and cerebrospinal fluid drained against a pressure
level of 15 mmHg. Hypotension was treated first with albumin
20% and crystalloid solutions and with Dobutamine if needed.
The goal was to keep CPP above 60 mmHg. Identified aneurysms
were treated early by endovascular coiling or surgical clipping. All
patients received nimodipine (Nimotop®, Bayer AB, Solna, Swe-
den). The patients were diagnosed to have DCI when delayed
ischemic neurological deterioration/deficits occurred that could
not be explained by other reasons, i.e., clot, hydrocephalus, or
infection. DCI was treated with hypertensive, hypervolemic, and
hemodilution therapy (triple-H therapy) by the administration
of Dextran 40 solutions 500 ml/day (Rheomacrodex®, 100 mg/ml,
Table 1 | Patient demographics and clinical characteristics of nine SAH
patients.
Patient Sex Age DCI H&H CT-
Fisher
Treatment GCS-M
in
GCS-M
out
1 F 51 No 1 3 Clipping 6 6
2 F 73 Yes 3 4c Coiling 6 4
3 F 64 Yes 3 4c Coiling 6 6
4 F 28 No 5 4a Coiling 1 6
5 F 56 Yes 4 4a Coiling 5 6
6 F 67 No 2 4a Coiling 6 4
7 M 54 Yes 4 4a Coiling 4 6
8 F 64 Yes 1 4a Coiling 6 5
9 F 49 Yes 2 4a Coiling 6 6
The Hunt & Hess grade is based on the status at admission and CT-fishers grade
is based on the initial CT. GCS-M, Glasgow coma scale motor response.
Meda AB, Solna, Sweden) and Albumin 100 ml,2× (200 mg/ml,
Baxter Medical AB, Kista, Sweden).
CBF MEASUREMENTS
As a part of the new protocol at our department, Xenon-CT is per-
formed bedside in the NIC unit on all patients with SAH within
the first 72 h after admission. CBF measurements using Xenon-CT
were performed bedside in our NIC unit according to the princi-
ples described by Yonas et al. (20–23). The Xenon gas is a radio
opaque, highly lipid soluble, and capable of crossing the BBB. The
Kety–Schmidt equation is applied to measure regional and global
CBF (24). Stable Xenon at a concentration of 28% was admin-
istered to the patients breathing circuit for about 4 min using
the Enhancer 3000 and computer software (Diversified Diagnostic
Products Inc., Houston, USA). During the Xenon inhalation, CT
scans were obtained by the CereTom® (Neurologica, Boston, USA).
The Xenon delivery and the CT scans were synchronized by com-
puter software and the resulting radiologic tissue enhancement of
the Xenon wash-in enabled CBF (ml/100 g/min) to be calculated
and plotted as colored maps in scans at four different levels of the
brain (eight scans per level, two baselines and six enhanced, with
10-mm spacing).
Mean blood flow in each of 20 evenly distributed cortical
regions (ROIs) was calculated for each level (Figure 1). The global
CBF is given as a mean of all four levels. The tip of the MD catheter
was identified on the structural CT scans and a ROI was drawn
manually for the corresponding area around the MD catheter on
the CBF scans (Figure 1). The vascular territories were analyzed
as following: anterior cerebral artery ROI 1–2 (right) and 19–20
(left), middle cerebral artery ROI 3–8 (right) and 13–18 (left),
and posterior cerebral artery ROI 9–10 (right) and 11–12 (left).
Territories with CT-defined hematoma or artifact were noted and
excluded.
CEREBRAL MICRODIALYSIS
The cerebral MD technique in NIC has previously been exten-
sively used and described (25, 26). The intracerebral MD catheter
was placed in the right frontal lobe cortex through a separate burr
hole, anterior to the ventricular drain. The anatomical location
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of the MD catheters was evaluated by CT scans. For intracerebral
monitoring, we used 70 Brain Microdialysis Catheter (M Dialy-
sis AB, Solna, Sweden) with a membrane length of 10 mm and
a membrane cutoff of 20,000 Da was used for intracerebral MD.
The catheters were perfused with artificial CSF (Na+, 147 mM;
Ca2+, 1.2 mM; Mg2+, 0.85 mM; K+, 2.7 mM; and Cl−, 152 mM).
The perfusion rate was 0.3µl/min using a microinjection pump
(CMA-106, M Dialysis AB, Solna, Sweden). MD urea was moni-
tored to validate catheter performance (27). The MD samples were
collected on an hourly basis. MD samples for the 3-h period before
and 3-h period after the Xenon-CT examination were used for
analysis. Interstitial glucose, lactate, pyruvate, glutamate, glycerol,
FIGURE 1 | At each level, CBF in 20 ROIs was calculated and averaged
for global CBF (lower left). The vascular territories were analyzed as
follows: anterior cerebral artery ROI 1–2 (lower right) and 19–20 (lower left),
middle cerebral artery ROI 3–8 (lower right) and 13–18 (lower left), and
posterior cerebral artery ROI 9–10 (lower right) and 11–12 (lower left). For
CBF around the microdialysis catheter, a ROI was manually drawn around
the microdialysis catheter after localization on CT-scan (lower right).
and urea were analyzed enzymatically using a CMA 600 analyzer
(M Dialysis AB, Solna, Sweden). Quality control measurements
using control samples for the CMA 600 microdialysis analyzer (M
Dialysis AB, Solna, Sweden) were run daily.
ETHICS
The Uppsala University Regional Ethical Review Board for clin-
ical research granted permission to undertake the study. Written
informed consent was obtained from all patients or their proxy
for study participation. The study was also approved by the local
Radiation Safety Authority.
RESULTS
Demographics and clinical characteristics of the nine SAH patients
studied are presented in Table 1. The Xenon-CT CBF measure-
ments were performed within the first 3 days (mean 2.9± 0.9) after
bleeding and no complications were observed during the measure-
ments. The physiological values during the CBF measurements
are presented in Table 2. The ICP and CPP were within normal
range 13.6± 3.4 mmHg and 77± 10.2 mmHg, respectively and
did not change compared to before and after CBF measurements
(Figure 2). None of the patients were hyperventilated during the
CBF measurements. The mean pCO2 was 5.1± 0.3 kPa and mean
pO2 was 13.9± 2.3 kPa. No significant changes could be observed
in ICP, CPP, and MAP during and after CBF measurements com-
pared with before. Six out of the nine patients developed DCI
according to the applied definition (Table 1).
GLOBAL CBF
The mean global CBF was 35± 20 ml/100 g/min (median= 25,
range 64) (Table 3). The correlations between global CBF and neu-
rological grade, CPP, pCO2, and amount of sedation, respectively,
are shown in Figure 3. Five out of six patients who developed
DCI had global CBF below 26 ml/100 g/min whereas one had
53 ml/100 g/min (Figure 4). Those three patients who did not
develop DCI all had global CBF above 27 ml/100 g/min. Due to
the low number of patients no statistics have been performed.
REGIONAL CBF
The results of CBF measurements in different vascular territo-
ries for each patient are presented in Table 3. The mean regional
Table 2 | Physiological parameters and neurological grade during the Xenon-CT CBF measurements are presented for each patient.
Patient ICP (mmHg) MAP (mmHg) CPP (mmHg) FIO2 (%) pCO2 (kPa) pO2 (kPa) Propofol (mg/kg/h) GCS-M
1 15.8 104.9 89.1 30 5.1 13.6 5.9 5
2 12.4 107.7 94.3 40 5.8 17.2 2.2 6
3 14.7 90.8 76.4 45 4.8 12.9 3.5 4
4 15.3 84.8 71.9 30 5.4 17.4 5.2 6
5 14.6 96.4 82.2 35 5.0 14.1 3.1 4
6 9.2 76.6 62.5 45 5.4 12.3 1.8 4
7 13.5 80.0 70.3 40 5.2 14.2 2.8 6
8 18.9 87.2 68.4 40 5.0 9.9 3.3 5
9 7.7 85.8 78.1 30 4.7 13.9 3.2 6
ICP, intracranial pressure; MAP, mean arterial pressure; CPP, cerebral perfusion pressure; FIO2, fraction of inspired oxygen; GCS-M, Glasgow coma scale motor score.
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CBF was 37± 22 (mean± SD) ml/100 g/min (median= 30,
range= 68) in the ACA territory, 34± 17 ml/100 g/min (median=
26, range= 80) in the PCA territory, 32± 20 ml/100 g/min
(median= 29, range= 60) in the MCA, and 28± 14 ml/100 g/min
(median= 23, range= 48) in the MD region (Table 3). No obvi-
ous lateralization of low CBF in relation to the aneurysm loca-
tion could be seen. There were individual differences in each
patient in different vascular territories, e.g., in patient 2 there
was a 50% decrease in the left posterior circulation compared
to global CBF while there was an increase in the right side.
Patient 5 showed a 24% decrease in CBF in the right anterior
circulation while there was a 15% increase in the right posterior
circulation. Four patients showed >20% difference between the
FIGURE 2 | Physiological parameters (CPP, cerebral perfusion pressure;
MAP, mean arterial pressure) and ICP (Intracranial pressure) in all nine
patients before and after Xenon-CT (indicated by the arrow). The values
are given as mean±SD.
two sides in the anterior circulation, one patient in the posterior
circulation and three patients in the middle vascular territory
(Table 3).
MICRODIALYSIS AND CBF
All patients had lower CBF in the region around the
catheter (28± 14 ml/100 g/min) compared to global CBF
(35± 20 ml/100 g/min) (Table 3). High lactate/pyruvate (L/P)
ratios tended to be correlated with lower CBF values in the
area surrounding the catheter and there appeared to be a criti-
cal CBF threshold at around 20 ml/100 g/min (Figure 5). Five out
of nine patients also had L/P ratio ≥25 four of these patients had
CBF≤ 22 ml/100 g/min. These four patients presented high glu-
tamate levels. No correlation was evident between glucose and
regional CBF (Figure 5). In patients 6 and 8, the glucose levels
were <1 mmol/l and these patients had CBF≤ 22 ml/100 g/min,
high L/P ratio, and high glutamate levels. In the patients who
develop DCI,five had CBF≤ 23 ml/100 g/min in the region around
the catheter. One with CBF 18 ml/100 g/min presented with L/P
ratio of 77 and glutamate 66µmol/l. Patient 8 displayed the
lowest CBF in the region around the catheter 10 ml/100 g/min
and had a L/P 48 and glutamate 28µmol/l. Patient 7 showed
CBF of 46 ml/100 g/min with low L/P ratio of 16 and glutamate
6µmol/l.
DISCUSSION
In this pilot study including nine SAH patients, the first results of
Xenon-CT CBF imaging bedside in combination with simultane-
ous monitoring of cerebral metabolism using MD are presented.
We found the use of bedside Xenon-CT feasible and useful in
assessing regional CBF in the NIC unit as reported by others (15,
28). No complications occurred during the CBF measurements
and the physiological parameters remained within their normal
ranges. A previous multicenter study reported the safety of this
method with a very low risk of adverse events (14). Using bedside
Table 3 | Aneurysm location and CBF in different regions.
Patient Aneurysm location Cerebral blood flow (ml/100 g/min)
Ant Post Middle Global MD
Right Left Right Left Right Left
1 Left MCA 49 (22) 48 (21) 42 (5) 44 (11) 44 (10) 45 (12) 45.4 34.9
2 ACA 31 (15) 26 (−1) 21 (−20) 23 (−14) 38 (41) 13 (−50) 25.5 23.1
3 ACA 18 (−23) 13 (−44) 23 (−4) 21 (−13) 32 (34) 20 (−16) 21.3 18.5
4 PICA 82 (12) 75 (2) 79 (8) 93 (27) 63 (−14) 74 (1) 77.6 58.6
5 A cerb sup 16 (−24) 24 (15) 27 (26) 23 (9) 20 (−8) 20 (−4) 21.7 19.2
6 ACA 23 (−19) 29 (6) 27 (−4) 27 (−4) 29 (3) 29 (3) 27.2 22.1
7 AcomA 56 (6) 62 (17) 44 (−17) 46 (−12) 53 (0) 54 (2) 52.6 42.6
8 AcomP+ ant 15 (4) 14 (−5) 18 (18) 25 (71) 10 (−32) 15 (2) 16.4 10.6
9 ICA right 45 (115) 33 (61) 13 (−40) 15 (−27) 21 (1) 21 (−1) 24.6 24
The changes in CBF between right and left side in different vascular regions compared to global CBF are presented in bracket (%). R, right; L, left; MCA, middle
cerebral artery; AcoA, anterior communicating artery; PcoA, posterior communicating artery; SCA, superior cerebellar artery; PICA, posterior inferior cerebellar artery;
MD, microdialysis region.
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FIGURE 3 |The figure presents correlations between global cerebral blood flow (CBF) and the amount of sedation (Propofol), neurological grade
(GCS-M, Glasgow coma scale motor score), pCO2, and cerebral perfusion pressure (CPP) during Xenon-CT measurements.
FIGURE 4 | Six out of nine patients developed DCI while three did not.
Patients that did not develop DCI tended to have higher initial CBF than
patients who did develop DCI.
Xenon-CT enables CBF measurements in unstable patients where
transportation to the radiology department is associated with
risks. The addition of bedside Xenon-CT CBF imaging to mul-
timodality monitoring creates new possibilities for more accurate
surveillance and guidance of treatment in NIC. More experience
with the technique is needed in order to develop new algorithms
for the NIC management.
The serious consequences of DCI following SAH are well
known, but it is difficult to identify patients at risk. Our
preliminary results suggest that patients with initial low global
CBF, below 27 ml/100 g/min, on Xenon-CT may be more likely to
develop DCI later. Previous studies using Xenon-CT have shown
that cortical CBF in awake normal subjects is 52± 10 ml/100 g/min
(21). In a study comparing comatose patients following head
injury and normal subjects, a CBF threshold of 55.3 ml/100 g/min
was defined as hyperemia derived from normal CBF distribution
(29). This study suggested CBF values 33.9–55.3 ml/100 g/min
as “relative hyperemia”. CBF threshold values vary among dif-
ferent authors. However, studies in animal and humans have
shown that CBF< 6 ml/100 g/min indicates severe ischemia and
will lead to infarction, CBF>6 and<18 ml/100 g/min are consid-
ered as reversible ischemia and CBF>18 and<33.9 ml/100 g/min
as reduced flow (29–31). In patients with clinical signs of DCI,
low regional CBF levels were measured by Xenon-CT and regions
with CBF below 15 ml/100 g/min developed to infarction (18).
Reduced global CBF (>18 and <33.9 ml/100 g/min) was seen
in patients who developed DCI in the current study when
Xenon-CT was performed within the first 72 h. Currently, the
triple-H therapy is initiated when clinical signs of vasospasm
occur. However, if further studies confirm and demonstrate
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FIGURE 5 | Illustrates correlation between microdialyzate
lactate/pyruvate (L/P) ratio and CBF, glucose and CBF, and glutamate
and CBF. The CBF values represent the area surrounding the microdialysis
catheter.
significant correlation between low initial CBF and development
of vasospasm, prophylactic treatment could be initiated at an ear-
lier stage in vulnerable patients at risk of irreversible cerebral
damage. Furthermore, the effect of vasospasm therapy could also
be evaluated.
The regional analysis of CBF showed decreased CBF in one or
more of the vascular territories in most of the SAH patients. This
finding is in accordance with an earlier PET study by Frykholm and
coll. demonstrating that heterogeneous disturbances of regional
CBF were present early after hemorrhage (1). The phenomenon
may also be a warning of future risk of vasospasm and/or an indi-
cation of an increased vulnerability for various secondary insults
(2). The underlying mechanisms for the observed reduced CBF
early after SAH deserve further investigation. Interestingly, the
suggested mechanisms may be disturbances in microcirculation
and occurrence of microthrombosis that leads to reduce blood
flow (32–35). This may also explain the findings of reduced CBF
in the current study.
Using MD, we observed high L/P ratio and high glutamate
levels when regional CBF was below 22 ml/100 g/min in the MD
region. Two previous smaller studies have combined MD with
Xenon-CT in SAH patients. The first study included 16 SAH
patients that underwent Xenon-CT during day 3–10. No corre-
lation could be found between L/P ratio and clinical status (36).
Two patients in this study who developed infarction in the region
of MD catheter had high glutamate levels. However, this study
in contrast to the current did not correlate CBF with L/P ratio
and CBF measurements were later than 72 h. In the second study,
Al-Rawi et al. investigated the effect of hypertonic saline infusion
on substrate delivery and metabolism by using MD and brain
tissue oxygen sensor (37). A decrease of L/P ratio was observed
in 9 out of 14 SAH patients after hypertonic saline infusion and
seven out of nine patients had an increase in CBF according to
Xenon-CT. Previous studies have also combined MD with PET in
order to assess both CBF and the metabolic state in SAH patients
(38–40). Interestingly, the L/P ratio has shown to be the most
sensitive and specific MD parameter to indicate ischemia (40).
Glutamate has been proposed as an early marker of threaten-
ing ischemia in SAH monitored by TCD (41). Using PET and
MD glutamate showed high sensitivity for detecting a critically
reduced regional CBF below 20 ml/100 g/min (40). These studies
are in accordance with findings in animal studies using PET and
MD (42).
We did not observe an evident correlation between glucose
and CBF, however, two patients with glucose levels <1 mmol/l
had CBF≤ 22 ml/100 g/min, high L/P ratio and high glutamate
levels. A low MD glucose level has been reported in SAH
patients who develop infarct, and zero values of glucose were
detected in patients with unfavorable outcome (43). Low regional
brain glucose can depend on low CBF as well as hypo- and
hypermetabolism.
CONCLUSION
The bedside Xenon-CT can be used safely for SAH patients in
conjunction with MD monitoring of cerebral metabolism. The
current pilot study includes few patients and therefore the results
must be interpreted with caution. The results indicate that reduced
CBF during the 72 h following symptom onset may be associated
with increased risk of DCI and also with elevated L/P ratio, which
is a marker of disturbed energy metabolism.
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